Cargando…

Clinical Trials of Repurposed Antivirals for SARS-CoV-2

The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has prompted the repurposing of drugs on the basis of promising in vitro and therapeutic results with other human coronavirus diseases, such as severe acute respiratory syndrome...

Descripción completa

Detalles Bibliográficos
Autor principal:	Martinez, Miguel Angel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2020
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7449177/ https://www.ncbi.nlm.nih.gov/pubmed/32631826 http://dx.doi.org/10.1128/AAC.01101-20

Ejemplares similares

What Should Be Learned From Repurposed Antivirals Against SARS-CoV-2?
por: Martinez, Miguel Angel
Publicado: (2022)

SARS-CoV-2 RNA polymerase as target for antiviral therapy
por: Buonaguro, Luigi, et al.
Publicado: (2020)

New Approaches and Repurposed Antiviral Drugs for the Treatment of the SARS-CoV-2 Infection
por: Bauso, Luana Vittoria, et al.
Publicado: (2021)

Combining antiviral drugs with BET inhibitors is beneficial in combatting SARS‐CoV‐2 infection
por: Acharya, Arpan, et al.
Publicado: (2022)

A comparative analysis of remdesivir and other repurposed antivirals against SARS‐CoV‐2
por: Simonis, Alexander, et al.
Publicado: (2020)

In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2
por: Pizzorno, Andrés, et al.
Publicado: (2020)

Drug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV
por: Aherfi, Sarah, et al.
Publicado: (2021)

Accelerated first-in-human clinical trial of EIDD-2801/MK-4482 (molnupiravir), a ribonucleoside analog with potent antiviral activity against SARS-CoV-2
por: Holman, Wendy, et al.
Publicado: (2021)

Plitidepsin: a Repurposed Drug for the Treatment of COVID-19
por: Martinez, Miguel Angel
Publicado: (2021)

Repurposing Nimesulide, a Potent Inhibitor of the B0AT1 Subunit of the SARS-CoV-2 Receptor, as a Therapeutic Adjuvant of COVID-19
por: Scalise, Mariafrancesca, et al.
Publicado: (2020)

Repurposing carrimycin as an antiviral agent against human coronaviruses, including the currently pandemic SARS-CoV-2
por: Yan, Haiyan, et al.
Publicado: (2021)

Pathogenicity of SARS‐CoV‐2 Omicron
por: Chu, Hin, et al.
Publicado: (2022)

Antigenic imprinting in SARS‐CoV‐2
por: Reincke, S. Momsen, et al.
Publicado: (2022)

Rapamycin: Drug Repurposing in SARS-CoV-2 Infection
por: Patocka, Jiri, et al.
Publicado: (2021)

Protecting clinical trials in cystic fibrosis during the SARS-CoV-2 pandemic: risks and mitigation measures
por: van Koningsbruggen-Rietschel, Silke, et al.
Publicado: (2021)

Antiviral Activity of Repurposing Ivermectin against a Panel of 30 Clinical SARS-CoV-2 Strains Belonging to 14 Variants
por: Delandre, Océane, et al.
Publicado: (2022)

SARS-CoV-2: An Update on Potential Antivirals in Light of SARS-CoV Antiviral Drug Discoveries
por: Elshabrawy, Hatem A.
Publicado: (2020)

Clinical characteristics of 9 cancer patients with SARS-CoV-2 infection
por: Zeng, Yong, et al.
Publicado: (2020)

L1000 connectivity map interrogation identifies candidate drugs for repurposing as SARS-CoV-2 antiviral therapies
por: Sendama, Wezi
Publicado: (2020)

Repurposing of Sitagliptin- Melittin Optimized Nanoformula against SARS-CoV-2; Antiviral Screening and Molecular Docking Studies
por: Al-Rabia, Mohammed W., et al.
Publicado: (2021)

Model-Informed Repurposing of Medicines for SARS-CoV-2: Extrapolation of Antiviral Activity and Dose Rationale for Paediatric Patients
por: Romano, Federico, et al.
Publicado: (2021)

Discovery of adapalene and dihydrotachysterol as antiviral agents for the Omicron variant of SARS-CoV-2 through computational drug repurposing
por: Fidan, Ozkan, et al.
Publicado: (2022)

A drug repurposing screen identifies hepatitis C antivirals as inhibitors of the SARS-CoV2 main protease
por: Baker, Jeremy D., et al.
Publicado: (2021)

In silico molecular docking analysis for repurposing approved antiviral drugs against SARS-CoV-2 main protease
por: Khater, Ibrahim, et al.
Publicado: (2021)

Repurposing of potential antiviral drugs against RNA-dependent RNA polymerase of SARS-CoV-2 by computational approach
por: Gangadharan, Sivakumar, et al.
Publicado: (2022)

SARS‐CoV‐2: March toward adaptation
por: Benedetti, Francesca, et al.
Publicado: (2020)

The pathogenesis and alternative treatment of SARS-CoV2
por: Choi, Jun-Yong, et al.
Publicado: (2020)

The prospects for the SARS‐CoV‐2 pandemic in Africa
por: Quaresima, Virginia, et al.
Publicado: (2020)

One year of SARS-CoV-2 evolution
por: Wu, Aiping, et al.
Publicado: (2021)

SARS CoV-2 load in periodontal disease
por: Sahni, Vaibhav
Publicado: (2022)

SARS-CoV-2 persistence at subzero temperatures
por: Scarica, Catello, et al.
Publicado: (2021)

Mitigating airborne transmission of SARS-CoV-2
por: Addleman, Sarah, et al.
Publicado: (2021)

In SARS-CoV-2, astrocytes are in it for the long haul
por: Huang, Shuhan, et al.
Publicado: (2022)

SARS-CoV-2 Antiviral Therapy
por: Tao, Kaiming, et al.
Publicado: (2021)

The SARS-CoV-2 pandemic puts the spotlight on gender inequality in clinical research
por: Søgaard, Mette, et al.
Publicado: (2021)

Collaboration between Clinical and Academic Laboratories for Sequencing SARS-CoV-2 Genomes
por: Wang, Jeremy, et al.
Publicado: (2022)

Anti–SARS‐CoV‐2 Repurposing Drug Database: Clinical Pharmacology Considerations
por: Zhang, Xinyuan, et al.
Publicado: (2021)

Comparative transcriptome analysis of SARS-CoV, MERS-CoV, and SARS-CoV-2 to identify potential pathways for drug repurposing
por: Krishnamoorthy, Pandikannan, et al.
Publicado: (2021)

Efficacy of repurposed antiviral drugs: Lessons from COVID-19
por: Martinez, Miguel Angel
Publicado: (2022)

Potential therapeutic targets for combating SARS-CoV-2: Drug repurposing, clinical trials and recent advancements
por: Pandey, Abhjieet, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_8fbuufsqqqess1m6rcl43be8ib